Tyzeka (telbivudine) / Novartis 
Welcome,         Profile    Billing    Logout  
 18 Diseases   8 Trials   8 Trials   244 News 


«12345»
  • ||||||||||  entecavir / Generic mfg., lamivudine / Generic mfg., Tyzeka (telbivudine) / Novartis
    Clinical, Journal:  Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study. (Pubmed Central) -  Oct 1, 2020   
    CHB Patients who had received NUCs antiviral treatment showed a slow but significant decrease in serum HBsAg level. Long-term monitoring and continuous antiviral treatment are necessary, especially for those patients with risk factors associated with HBsAg decline.
  • ||||||||||  lamivudine / Generic mfg.
    Journal:  Evidence for Use of Tenofovir in Pregnancy to Prevent Perinatal Transmission of Hepatitis B Infection. (Pubmed Central) -  Sep 9, 2020   
    This chapter is a review of current studies that, ultimately, have provided strong evidence for the efficacy and safety of 3 antiviral drugs in pregnancy-lamivudine, telbivudine and tenofovir. The latter drug is the particular focus of this chapter which will show that tenofovir is the preferred antiviral therapy in pregnant women because of its potency, safety profile, and low risk of resistance.
  • ||||||||||  lamivudine / Generic mfg.
    Clinical, Journal:  Identification and molecular-genetic characteristics of the hepatitis B virus among HIV-infected patients in Arkhangelsk. (Pubmed Central) -  Jul 29, 2020   
    For pregnant women with HBV DNA≥10 copies/mL, the use of LdT during late pregnancy could effectively reduce the MTCT rate of HBV. The occult (HBsAg-negative) HBV high prevalence among HIV-infected patients suggests the need to use molecular-biological diagnostic methods to identify HBV, as well as to analyze the HBV drug resistance mutation before starting antiretroviral therapy for HIV.
  • ||||||||||  Tyzeka (telbivudine) / Novartis
    Clinical, Journal:  Efficacy and safety of telbivudine treatment for the prevention of HBV perinatal transmission. (Pubmed Central) -  Jul 3, 2020   
    No statistical differences were observed between the 2 groups regarding maternal cesarean section rate, adverse pregnancy rate, postpartum bleeding rate, neonatal body mass, Apgar score, neonatal malformation incidence, or intelligence development of newborn.Telbivudine is effective to reduce the viral load in CHB mothers with high viral load and could lower the perinatal transmission rate. Both mental and physical development in neonates with exposure to telbivudine during perinatal period were similar to those without telbivudine exposure.
  • ||||||||||  entecavir / Generic mfg., Tyzeka (telbivudine) / Novartis
    Clinical, Retrospective data, Journal:  Efficacy of telbivudine and entecavir against virus reactivation in HBeAg-patients undergoing chemotherapy. (Pubmed Central) -  Jul 1, 2020   
    The overall likelihood of being helped over being harmed was 2.77. With careful selection of patients with the criteria of HBeAg-status and non-hematologic cancer, it is feasible that telbivudine raise lower probability of virological breakthroughs during prophylaxis treatment.
  • ||||||||||  lamivudine / Generic mfg.
    Journal:  Primary Resistance of Hepatitis B Virus to Nucleoside and Nucleotide Analogues. (Pubmed Central) -  Jun 29, 2020   
    RASs at positions involved in lamivudine, telbivudine and adefovir resistance were the most frequently detected. All patients with RASs detectable by NGS at baseline who were treatment-eligible and treated with currently recommended drugs achieved a virological response.The presence of preexisting HBV RASs has no impact on the outcome of therapy if potent drugs with a high barrier to resistance are used.
  • ||||||||||  lamivudine / Generic mfg., ATI-2173 / Antios Therap
    [VIRTUAL] ATI-2173, a novel phosphoramidate nucleoside prodrug for HBV cure regimens (Poster Area) -  May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1825;    
    ATI-2173 is a potent liver-targeted molecule that delivers the 5’-monophosphate of clevudine, enhancing the anti-HBV activity while significantly reducing systemic exposure to clevudine in the rat and monkey. ATI-2173 combined with TDF, ETV or other direct acting antivirals, could become an integral part of combination HBV cure regimens.
  • ||||||||||  Tyzeka (telbivudine) / Novartis
    [VIRTUAL] Hepatocyte-derived l-carnitine impedes HBsAg clearance in chronic HBV infection (Poster Area) -  May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1266;    
    HBeAg-positive CHB patients who participated in clinical trial with telbivudine treatment were classified into either a complete response (CR) group or a noncomplete response (NCR) group based on the status of HBeAg and HBV DNA at 48 weeks... L-Cn released from the injured hepatocytes displays immune suppressive properties and impedes HBsAg clearance, implicating that L-Cn may serve as a potentially therapeutic target for HBV infection.
  • ||||||||||  Copegus (ribavirin) / Bausch Health, Tyzeka (telbivudine) / Novartis
    FDA event, Journal:  Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. (Pubmed Central) -  Apr 30, 2020   
    Ribavirin, telbivudine, vitamin B12 and nicotinamide can be combined and used for COVID treatment. This initiative relocates already marketed and approved safe drugs for potential use in COVID-treatment.
  • ||||||||||  Journal:  Toxic Myopathies. (Pubmed Central) -  Apr 22, 2020   
    Certain clinical, electrodiagnostic, and histologic features can aid in early recognition. Stopping the use of the offending agent reverses symptoms in most cases, but specific and timely treatment may be required in cases related to agents that trigger immune-mediated muscle injury.
  • ||||||||||  lamivudine / Generic mfg., Vemlidy (tenofovir alafenamide) / Gilead
    Journal:  Unmet need in chronic hepatitis B management. (Pubmed Central) -  Mar 26, 2020   
    Preemptive antiviral treatment may reduce mother-to-child transmission of hepatitis B virus, especially if birth dose of vaccination cannot be given in the first two hours after delivery. Lastly, despite the currently first-line NAs have high-genetic barrier to drug resistance mutations, there are still are many patients who were previously treated with low barrier of resistance including lamivudine, telbivudine or adefovir dipivoxil which could lead to antiviral resistance and affecting the choice of NAs.
  • ||||||||||  lamivudine / Generic mfg.
    Review, Journal:  Hepatitis B and Pregnancy: Virologic and Immunologic Characteristics. (Pubmed Central) -  Feb 8, 2020   
    Viral rebound usually occurs after stopping treatment and, in the context of maternal immunologic reconstitution postpartum, can also precipitate host immune-mediated hepatic (biochemical) flares. In this article, we review the epidemiology of HBV MTCT, discuss management and potential mechanisms of HBV vertical transmission, and highlight recent studies on virologic and immunologic aspects of hepatitis B in pregnancy and postpartum.
  • ||||||||||  lamivudine / Generic mfg.
    Clinical, Journal:  Evaluation of the pol/S Gene Overlapping Mutations in Chronic Hepatitis B Patients in Northern Cyprus. (Pubmed Central) -  Jan 16, 2020   
    These data underscored that there is no concern for primary mutations in Northern Cyprus, however, we have identified a compensatory mutation (rtV173M) that may have primary mutation characteristics by combining with other mutation patterns. Additionally, HBsAg escape mutants demonstrated that detection of the S gene together with the pol gene mutations might be beneficial and important to monitor the surveillance of S variants.
  • ||||||||||  Tyzeka (telbivudine) / Novartis
    Biomarker, Journal:  The serum interleukin-26 level is a potential biomarker for chronical hepatitis B. (Pubmed Central) -  Jan 16, 2020   
    Proinflammatory interleukin-26 (IL-26) is involved in chronic inflammation; however, the role of IL-26 in chronic hepatitis B (CHB) remains unknown.In this study, serum IL-26 was quantified in a cohort of CHB patients at baseline and during telbivudine (LdT) treatment.Our results showed that the serum IL-26 level was significantly elevated in CHB patients compared with that in healthy controls and was time-dependently decreased during LdT treatment, accompanying hepatitis B e antigen (HBeAg) seroconversion and reduced serum levels of hepatitis B virus (HBV) DNA, aspartate transaminase, and alanine transaminase across baseline and treatment...The percentage of IL-26-expressing CD4 cells was significantly higher than that of IL-26-expressing CD4 cells isolated from the peripheral blood mononuclear cells of CHB patients, suggesting that serum IL-26 might be mainly released from CD4 T cells. Furthermore, the baseline mRNA levels of IL-26 and orphan nuclear receptor RORγt-an important transcription factor expressed by Th17 cells-were positively correlated and displayed the same declining trend across the baseline and LdT treatment in CHB patients, suggesting that Th17 cells could be a possible cellular source of the increased serum IL-26 in CHB patients.Taken together, our results suggest that serum IL-26, possibly produced by Th17 CD4 cells, is a novel and potential biomarker for CHB prognosis and treatment.
  • ||||||||||  lamivudine / Generic mfg.
    Retrospective data, Journal, Adverse events:  Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs. (Pubmed Central) -  Jan 4, 2020   
    Furthermore, the baseline mRNA levels of IL-26 and orphan nuclear receptor RORγt-an important transcription factor expressed by Th17 cells-were positively correlated and displayed the same declining trend across the baseline and LdT treatment in CHB patients, suggesting that Th17 cells could be a possible cellular source of the increased serum IL-26 in CHB patients.Taken together, our results suggest that serum IL-26, possibly produced by Th17 CD4 cells, is a novel and potential biomarker for CHB prognosis and treatment. The findings from this large NMA could influence clinical practice, and the methodological framework of this study could provide evidence-based support to analyze sparse safety data in the field.
  • ||||||||||  Tyzeka (telbivudine) / Novartis
    Preclinical, Journal:  Tryptophan 32 mediates SOD1 toxicity in a in vivo motor neuron model of ALS and is a promising target for small molecule therapeutics. (Pubmed Central) -  Dec 2, 2019   
    Along with testing 5'-FUrd and uridine, a lead candidate from this list was selected based on its lower toxicity and improved blood brain barrier penetrance; telbivudine significantly rescued SOD1 toxicity in a dose-dependent manner...By substituting W32 for a more evolutionarily conserved residue (serine), we confirmed the significant influence of W32 on human SOD1 toxicity to motor neuron morphology and function; further, we performed pharmaceutical targeting of the W32 residue for rescuing SOD1 toxicity. This unique residue offers future novel insights into SOD1 stability and toxic gain of function, and therefore poses an potential target for drug therapy.
  • ||||||||||  lamivudine / Generic Mfg.
    Clinical, Journal:  Effects of Treatment of Chronic HBV Infection on Patient-reported Outcomes. (Pubmed Central) -  Nov 19, 2019   
    In an analysis of data from phase 2 trials, we associated active treatment of chronic HBV infection with increased PRO scores. These findings support inclusion of PRO endpoints in assessments of efficacy and safety in clinical trials of treatments for HBV infection.
  • ||||||||||  lamivudine / Generic Mfg.
    INCIDENCE OF BIRTH DEFECT AMONG PREGNANT WOMEN UNDER DIFFERENT ANTIVIRAL AGENTS FOR HEPATITIS B VIRUS (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_1909;    
    The rate of birth defect in adefovir and entecavir is still uncertain restricted by small sample size., while the animal experiments of adefovir and entecavir have showed teratogenic effects. Comprehensive consideration, both mothers’ and infants’ safety, should be taken when selecting antiviral agents during pregnancy.